

Table S1: Proportions of pSLE patients having high titer anti-matrigel antibodies, subdivided into groups either without or with clinical evidence meeting each particular ACR criteria, at any time in their disease course ¹

Antibody Subtype	ACR Criterion	Proportion of patients having high titer Ab		
		without	with	<i>P</i> -value ²
IgG	Malar rash	3/4 (75%)	5/6 (83%)	1.00
	Discoid rash	7/8 (88%)	1/2 (50%)	0.38
	Photosensitivity	5/7 (71%)	3/3 (100%)	1.00
	Mouth ulcers	5/7 (71%)	3/3 (100%)	1.00
	Arthritis	1/1 (100%)	7/9 (78%)	1.00
	Serositis	6/7 (86%)	2/3 (67%)	1.00
	Neurologic disorder	5/7 (71%)	3/3 (100%)	1.00
	Kidney disorder	5/6 (83%)	3/4 (75%)	1.00
	Hematologic disorder	3/3 (100%)	5/7 (71%)	1.00
IgM	Malar rash	4/4 (100%)	5/6 (83%)	1.00
	Discoid rash	8/8 (100%)	1/2 (50%)	0.20
	Photosensitivity	6/7 (86%)	3/3 (100%)	1.00
	Mouth ulcers	6/7 (86%)	3/3 (100%)	1.00
	Arthritis	1/1 (100%)	8/9 (89%)	1.00
	Serositis	6/7 (86%)	3/3 (100%)	1.00
	Neurologic disorder	6/7 (86%)	3/3 (100%)	1.00
	Kidney disorder	5/6 (83%)	4/4 (100%)	1.00
	Hematologic disorder	3/3 (100%)	6/7 (86%)	1.00
IgA	Malar rash	1/4 (25%)	2/6 (33%)	1.00
	Discoid rash	2/7 (29%)	1/2 (50%)	1.00
	Photosensitivity	1/7 (14%)	2/3 (67%)	0.18
	Mouth ulcers	1/7 (14%)	2/3 (67%)	0.18
	Arthritis	1/1 (100%)	2/9 (22%)	0.30
	Serositis	2/7 (29%)	1/3 (33%)	1.00
	Neurologic disorder	3/7 (43%)	0/3 (0%)	0.48
	Kidney disorder	2/6 (33%)	1/4 (25%)	1.00
	Hematologic disorder	2/3 (67%)	1/7 (14%)	0.18
IgG3	Malar rash	1/4 (25%)	2/6 (33%)	1.00
	Discoid rash	2/8 (25%)	1/2 (50%)	1.00
	Photosensitivity	3/7 (43%)	0/3 (0%)	0.48
	Mouth ulcers	3/7 (43%)	0/3 (0%)	0.48
	Arthritis	1/1 (100%)	2/9 (22%)	0.30
	Serositis	2/7 (29%)	1/3 (33%)	1.00
	Neurologic disorder	2/7 (29%)	1/3 (33%)	1.00
	Kidney disorder	1/6 (17%)	2/4 (50%)	0.50
	Hematologic disorder	1/3 (33%)	2/7 (29%)	1.00

¹ Number of patients with high titer anti-matrigel antibodies, defined as end-point titer >1:40, divided by the total number of patients, without or with each ACR criterion.

² *P*-value comparing the proportions of patients with high anti-matrigel titer between groups with and without ACR criteria using Fisher's exact test.

Table S2: Proportions of samples from pSLE patients having high titer anti-matrigel antibodies, subdivided into groups either without or with clinical findings suggestive of renal injury, at the time of sampling ¹

Antibody Subtype	Clinical Finding	Proportion of patients having high titer Ab		
		without	with	<i>P</i> -value ²
IgG	Hypocomplementemia	3/8 (38%)	5/9 (56%)	0.64
	Proteinuria	5/12 (42%)	3/5 (60%)	0.62
	Hematuria	6/14 (43%)	2/3 (67%)	0.58
	Anti-ds DNA Ab +	5/9 (56%)	3/8 (38%)	0.64
	Anti-RNP Ab +	6/15 (40%)	2/2 (100%)	0.21
IgM	Hypocomplementemia	4/8 (50%)	6/9 (67%)	0.35
	Proteinuria	5/12 (42%)	5/5 (100%)	0.04
	Hematuria	8/14 (57%)	2/3 (67%)	1.00
	Anti-ds DNA Ab +	2/9 (22%)	8/8 (100%)	< 0.01
	Anti-RNP Ab +	8/15 (53%)	2/2 (100%)	0.49
IgA	Hypocomplementemia	2/8 (25%)	1/9 (11%)	0.58
	Proteinuria	2/12 (17%)	1/5 (20%)	1.00
	Hematuria	2/14 (14%)	1/3 (33%)	0.46
	Anti-ds DNA Ab +	2/9 (22%)	1/8 (13%)	1.00
	Anti-RNP Ab +	1/15 (7%)	2/2 (100%)	0.02
IgG3	Hypocomplementemia	2/8 (25%)	3/9 (33%)	1.00
	Proteinuria	2/12 (17%)	3/5 (60%)	0.12
	Hematuria	4/14 (29%)	1/3 (33%)	1.00
	Anti-ds DNA Ab +	2/9 (22%)	3/8 (38%)	0.62
	Anti-RNP Ab +	3/15 (20%)	2/2 (100%)	0.07
All Isotypes	Hypocomplementemia	1/8 (13%)	0/9 (0%)	0.47
	Proteinuria	1/12 (8%)	0/5 (0%)	1.00
	Hematuria	1/14 (7%)	0/3 (0%)	1.00
	Anti-ds DNA Ab +	0/9 (0%)	1/8 (13%)	0.47
	Anti-RNP Ab +	1/15 (7%)	0/2 (0%)	1.00

¹ Number (and percentage) of patients with high titer anti-matrigel antibodies, defined as end-point titer >1:40, divided by the total number of patients without or with each clinical finding.

² *P*-value comparing the proportions of patients with high anti-matrigel titer between groups without and with each clinical finding, using Fisher's exact test.

